IP Library › Granted Patent US 12,303,285
Granted Patent B2
US 12,303,285 · App. 18/506,901 · Granted May 20, 2025

Methods and magnetic imaging devices to inventory human brain cortical function

Inventors: John P. Ford (Unadilla, NY); Gustavo P. Sudre (Washington, DC)
Assignee: Brain F.I.T. Imaging, LLC
A61B5/4088A61B5/0042A61B5/055A61B5/246A61B5/6803A61B5/7203A61B5/7257A61B5/7264A61B5/7267A61B5/162A61B2503/40A61B2560/0223A61B2562/0223A61B2576/026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,285
App. No.
18/506,901
Granted
May 20, 2025
Kind
B2
Abstract

Techniques are described for determining cognitive impairment, an example of which includes accessing a set of epochs of magnetoencephalography (MEG) data of responses of a brain of a test patient to a plurality of auditory stimulus events; processing the set of epochs to identify parameter values one or more of which is based on information from the individual epochs without averaging or otherwise collapsing the epoch data. The parameter values are input into a model that is trained based on the parameters to determine whether the test patient is cognitively impaired.

Claims (53)

1. A method comprising:

accessing, by a processor, a set of epochs of electrical data of responses of a brain of a test patient to a plurality of auditory stimulus events;

determining, by the processor and for each epoch, a characteristic of a sorting peak in a tri-peak pattern, the tri-peak pattern comprising a first peak, a second peak, and a third peak, the sorting peak being one of the first peak, the second peak, or the third peak;

sorting, by the processor, the set of epochs based on values of the characteristic of the sorting peak of the epochs;

determining, by the processor, one or more parameters of the set of epochs that are sorted, each of the one or more parameters related to one or more of the first peak, the second peak, or the third peak; and

providing, by the processor and based on the one or more parameters, a determination whether the test patient is cognitively impaired.

2. The computer-implemented method of claim 1 , wherein determining the characteristic of the sorting peak for at least one of the epochs comprises:

determining a timing window, and

determining an amplitude of a peak in the timing window as the characteristic.

3. The computer-implemented method of claim 1 , further comprising:

transmitting data representing the set of epochs that are sorted as a visualization of a heat map for display.

4. The computer-implemented method of claim 1 , further comprising:

determining an amplitude of the first peak, the second peak, or the third peak for each of the epochs based on the set of epochs that are sorted.

5. The computer-implemented method of claim 1 , determining the characteristic of the sorting peak comprises:

assigning a normalized maximum value based on a maximum value of amplitude of the sorting peak for each of the epochs in the set.

6. The computer-implemented method of claim 1 , wherein sorting the set of epochs comprises:

estimating initial peak boundaries for the set of epochs,

sorting the set of epochs based on the characteristic of the sorting peak defined by the initial peak boundaries, and

selecting a cutoff epoch for delineating between epochs that are determined to have and to not have the sorting peak.

7. The computer-implemented method of claim 1 , wherein at least one of the parameters is a number of the first peak, the number of the second peak, or the number of the third peak presented in the set of epochs, and determining the at least one of the parameters comprises:

generating a real heat map that sorts the set of epochs based on the characteristic of the sorting peak, and

comparing the real heat map to a plurality of ideal heat maps, each ideal heat map associated with a candidate cutoff epoch,

determining spatial correlation between the real heat map and each of the ideal heat maps,

selecting, based on the spatial correlation, one of the ideal heat maps, and

using the candidate cutoff epoch of the selected ideal heat map to determine the at least one of the parameters.

8. The computer-implemented method of claim 1 , wherein the electrical data is generated by a magnetoencephalography (MEG) device that comprises a plurality of sensors.

9. The computer-implemented method of claim 1 , wherein the set of epochs of the electrical data is generated by one of the sensors, and selecting the one of the sensors is based on stability of the responses of the test patient to the plurality of auditory stimulus events.

10. The computer-implemented method of claim 1 , wherein the set of epochs of the electrical data is generated by one of the sensors, and selecting the one of the sensors is based on reproducibility of a feature in the responses.

11. The computer-implemented method of claim 1 , wherein the one or more parameters comprises one or more of the following: an amplitude, a count of peaks, an area under curve, an onset value, an offset value, a latency, a variability, or a duration.

12. The computer-implemented method of claim 1 , wherein the first peak is a type-A peak, a type-B peak, or a type-C peak, and the second peak is a different one of those peaks.

13. The computer-implemented method of claim 1 , wherein providing the determination whether the test patient is cognitively impaired comprises inputting the one or more parameters to a machine learning model that performs the determination.

14. The computer-implemented method of claim 13 , wherein the machine learning model includes at least one of a random forest model, a gradient boosting model, a support vector machine (SVM) model, a linear SVM model, a radial basis function kernel SVM, a linear regression, a logistic regression, or a neural network.

15. A system comprising:

a sensor device configured to transmit a plurality of auditory stimulus events to a test patient and to measure responses of the test patient to generate at least a set of epochs of electrical data; and

a computing device that comprises one or more processors and memory configured to store instructions, the instructions, when executed by the one or more processors, cause the one or more processors to perform at least:

access the set of epochs of electrical data,

determine, for each epoch, a characteristic of a sorting peak in a tri-peak pattern, the tri-peak pattern comprising a first peak, a second peak, and a third peak, the sorting peak being one of the first peak, the second peak, or the third peak,

sort the set of epochs based on values of the characteristic of the sorting peak of the epochs,

determine one or more parameters of the set of epochs that are sorted, each of the one or more parameters related to one or more of the first peak, the second peak, or the third peak, and

provide, based on the one or more parameters, a determination whether the test patient is cognitively impaired.

16. The system of claim 15 , wherein the instructions, when executed by the one or more processors, cause the one or more processors to further perform at least:

transmitting data representing the set of epochs that are sorted as a visualization of a heat map for display.

17. The system of claim 15 , wherein the sensor device comprises a plurality of sensors.

18. The system of claim 17 , wherein the set of epochs of the electrical data is generated by one of the sensors, and selecting the one of the sensors is based on stability of the responses of the test patient to the plurality of auditory stimulus events.

19. The system of claim 17 , wherein the set of epochs of the electrical data is generated by one of the sensors, and selecting the one of the sensors is based on reproducibility of a feature in the responses.

20. A system comprising:

a computing device that comprises one or more processors and memory configured to store instructions, the instructions, when executed by the one or more processors, cause the one or more processors to perform at least:

access a set of epochs of electrical data of responses of a test patient to a plurality of auditory stimulus events,

determine, for each epoch, a characteristic of a sorting peak in a tri-peak pattern, the tri-peak pattern comprising a first peak, a second peak, and a third peak, the sorting peak being one of the first peak, the second peak, or the third peak,

sort the set of epochs based on values of the characteristic of the sorting peak of the epochs,

determine one or more parameters of the set of epochs that are sorted, each of the one or more parameters related to one or more of the first peak, the second peak, or the third peak, and

provide, based on the one or more parameters, a determination whether the test patient is cognitively impaired; and

a user interface in communication with the computing device, the user interface configured to display the determination.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: FORD, JOHN P.; SUDRE, GUSTAVO P.
To: BRAIN F.I.T. IMAGING, LLC
Reel/Frame 066412/0642 →
Continuity (4)
Continuation 16919094 · Jul 1, 2020
Continuation 15472130 · Mar 28, 2017
Provisional Application 62315376 · Mar 30, 2016
Related Publication 20240074692A1 · Mar 7, 2024
References Cited (216)
US 3445760A · Zimmerman · 1969 [cited by applicant]
US 3506913A · Lambe et al. · 1970 [cited by applicant]
US 3676718A · Anderson et al. · 1972 [cited by applicant]
US 3689780A · Meissner et al. · 1972 [cited by applicant]
US 3936677A · Fulton et al. · 1976 [cited by applicant]
US 4736751A · Gevins et al. · 1988 [cited by applicant]
US 4862359A · Trivedi et al. · 1989 [cited by applicant]
US 5325862A · Lewis et al. · 1994 [cited by applicant]
US 5326764A · Milstone et al. · 1994 [cited by applicant]
US 5381791A · Qian · 1995 [cited by applicant]
US 5713354A · Warden · 1998 [cited by applicant]
US 5752514A · Okamura et al. · 1998 [cited by applicant]
US 6192276B1 · Strandberg · 2001 [cited by applicant]
US 6195576B1 · John · 2001 [cited by applicant]
US 6230037B1 · Tsukada et al. · 2001 [cited by applicant]
US 6256531B1 · Ilmoniemi et al. · 2001 [cited by applicant]
US 6471960B1 · Anderson · 2002 [cited by applicant]
US 6473518B1 · Machida et al. · 2002 [cited by applicant]
US 6665553B2 · Kandori et al. · 2003 [cited by applicant]
US 6724188B2 · Butters et al. · 2004 [cited by applicant]
US 6745063B2 · Tsukada et al. · 2004 [cited by applicant]
US 6784663B2 · Sarwinski et al. · 2004 [cited by applicant]
US 6979688B2 · Ford · 2005 [cited by applicant]
US 6995165B2 · Ford · 2006 [cited by applicant]
US 7002341B2 · Baudenbacher et al. · 2006 [cited by applicant]
US 7130675B2 · Ewing et al. · 2006 [cited by applicant]
US 7197352B2 · Gott et al. · 2007 [cited by applicant]
US 7368456B2 · Ford · 2008 [cited by applicant]
US 7662829B2 · Ford · 2010 [cited by applicant]
US 7812030B2 · Ford · 2010 [cited by applicant]
US 7816366B2 · Ford · 2010 [cited by applicant]
US 8030710B2 · Pidin · 2011 [cited by applicant]
US 8258147B2 · Ford · 2012 [cited by applicant]
US 8489544B2 · Ford · 2013 [cited by applicant]
US 8653090B2 · Ford · 2014 [cited by applicant]
US 9084788B2 · Ford · 2015 [cited by applicant]
US 9095266B1 · Fu · 2015 [cited by applicant]
US 9119855B2 · Ford · 2015 [cited by applicant]
US 9286443B2 · Ford et al. · 2016 [cited by applicant]
US 10588576B2 · Phillips · 2020 [cited by examiner]
US 10736557B2 · Ford et al. · 2020 [cited by applicant]
US 11337631B2 · Ford et al. · 2022 [cited by applicant]
US 20020115927A1 · Tsukada et al. · 2002 [cited by applicant]
US 20020175693A1 · Starr et al. · 2002 [cited by applicant]
US 20030042898A1 · Sarwinski et al. · 2003 [cited by applicant]
US 20030100844A1 · Miller et al. · 2003 [cited by applicant]
US 20030158128A1 · Ford · 2003 [cited by applicant]
US 20040002645A1 · Ewing et al. · 2004 [cited by applicant]
US 20040145366A1 · Baudenbacher et al. · 2004 [cited by applicant]
US 20040171960A1 · Musha et al. · 2004 [cited by applicant]
US 20040254443A1 · Gott et al. · 2004 [cited by applicant]
US 20050124863A1 · Cook · 2005 [cited by applicant]
US 20050215514A1 · Ford · 2005 [cited by applicant]
US 20070015728A1 · Ford · 2007 [cited by applicant]
US 20070032737A1 · Causevic et al. · 2007 [cited by applicant]
US 20070038067A1 · Kandori et al. · 2007 [cited by applicant]
US 20080249430A1 · John · 2008 [cited by examiner]
US 20090018431A1 · Feiweier et al. · 2009 [cited by applicant]
US 20090062676A1 · Kruglikov · 2009 [cited by examiner]
US 20090232884A1 · Ford · 2009 [cited by applicant]
US 20100203140A1 · Ford · 2010 [cited by applicant]
US 20100280334A1 · Carlson et al. · 2010 [cited by applicant]
US 20110077260A1 · Ford · 2011 [cited by applicant]
US 20110190621A1 · Verdoorn et al. · 2011 [cited by applicant]
US 20120084919A1 · McCroskey et al. · 2012 [cited by applicant]
US 20120271148A1 · Nelson · 2012 [cited by applicant]
US 20130041590A1 · Burich · 2013 [cited by examiner]
US 20130245422A1 · D'Arcy et al. · 2013 [cited by applicant]
US 20140000630A1 · Ford · 2014 [cited by applicant]
US 20140081347A1 · Nelson et al. · 2014 [cited by applicant]
US 20150313901A1 · Ford · 2015 [cited by applicant]
US 20160045128A1 · Sitt et al. · 2016 [cited by applicant]
US 20160081577A1 · Sridhar · 2016 [cited by examiner]
US 20160157742A1 · Huang et al. · 2016 [cited by applicant]
US 20170224241A1 · Chen · 2017 [cited by applicant]
US 20170281071A1 · Ford et al. · 2017 [cited by applicant]
US 20200164201A1 · Berenyi et al. · 2020 [cited by applicant]
US 20200321124A1 · Ford et al. · 2020 [cited by applicant]
CN 101583308A · 2009 [cited by applicant]
CN 101912255A · 2010 [cited by applicant]
CN 105852885A · 2016 [cited by applicant]
EP 1447045A1 · 2004 [cited by applicant]
EP 1948014B1 · 2017 [cited by applicant]
JP 2015527111A · 2015 [cited by applicant]
WO WO2005039585A1 · 2005 [cited by applicant]
WO WO2007008858A2 · 2007 [cited by applicant]
WO WO2009149246A1 · 2009 [cited by applicant]
WO WO2013155385A1 · 2013 [cited by applicant]
WO WO2014004365A2 · 2014 [cited by applicant]
WO WO2017172961A1 · 2017 [cited by applicant]
WO WO2018163178A1 · 2018 [cited by applicant]
WO WO2019070895A1 · 2019 [cited by applicant]
Bagić et al., “Clinical Magnetoencephalography Practice in the United States Ten Years Later: A Survey-Based Reappraisal,” [cited by applicant]
Bardy, F. et al., “Deconvolution of magnetic acoustic change complex (mACC),” Clinical Neurophysiology, Elsevier, IE, vol. 125, No. 11, Mar. 13, 2014, pp. 1-12. [cited by applicant]
Barrows, parts of “Antineoplastic and Immunoactive Drugs,” Chapter 86 in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro et al. (eds.), Lippincott, Williams & Wilkins, Baltimore, MD, 2000, only pp… [cited by applicant]
Beers et al. (eds.), Chapter 126 (“Malignant Tumors”) in The Merck Manual of Diagnosis and Therapy, 17th Edition, Merck & Co., Inc., Rahway, NJ, Jan. 1999, only title pages and text pp. 842-843 supplied. [cited by applicant]
Berendse, H.W. et al., “Magnetoencephalographic Analysis of Cortical Activity in Alzheimer's Disease: a Pilot Study”, Clinical Neurophysiology, 2000, pp. 604-612, vol. 111. [cited by applicant]
Bland J.M. et al., “Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement,” Lancet, 1986, pp. 307-310, vol. 327, No. 8476. [cited by applicant]
Boly, M. et al., “Preserved Feedforward but Impaired Top-Down Processes in the Vegetative State”, Science, May 13, 2011, pp. 858-862, vol. 332. [cited by applicant]
Borg, X., “The Inverse Cube Law for Dipoles,” The General Science Journal, Jan. 25, 2009, 2 pages, May be Retrieved at <URL:http://blazelabs.com/inversecubelaw.pdf>. [cited by applicant]
Calabresi et al., “Chemotherapy of Neoplastic Diseases,” Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, 1996, Section X, pp. 1225-1229. [cited by applicant]
Cao et al., “5-Fluorouracil Prodrug: Role of Anabolic and Catabolic Pathway Modulation in Therapy of Colorectal Cancer,” Clinical Cancer Research, 1995, pp. 839-845, vol. 1, No. 8. [cited by applicant]
Cheour, M. et al., “Magnetoencephalography is feasible for infant assessment of auditory discrimination,” Sep. 15, 2004, [cited by applicant]
Childress, J. et al., “Cutaneous Hand and Foot Toxicity Associated with Cancer Chemotherapy,” American Journal of Clinical Oncology, vol. 26(5), pp. 435-436, 2003. [cited by applicant]
Chua, D. et al., “Efficacy of Capecitabine Monotherapy in Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma Pretreated with Platinum-Based Chemotherapy,” Proc. Am. Soc. Clin. Oncol., vol. 22, p. 511, 2003. [cited by applicant]
Clarke, A. et al., “Predicting the Time Course of Individual Objects with MEG,” Cerebral Cortex, Oxford Journals, Sep. 2014, 12 pages. [cited by applicant]
Demopoulos, C., et al., “Magnetoencephalographic Imaging of Auditory and Somatosensory Cortical Responses in Children with Autism and Sensory Processing Dysfunction,” [cited by applicant]
Ehrlanger et al., “Cutaneous Absorption and Urinary Excretion of 6-14C-5-5-Fluorouracil Ointment Applicated in an Ointment to Healthy and Diseased Human Skin,” Dermatologics, vol. 140, Suppl. 1, pp. 129-136, 1970. [cited by applicant]
Elasmer et al., “Case Report: Hand-Foot Syndrome Induced by Oral Fluoropyrimidine S-1,” Jpn. J. Clin. Oncol., vol. 3(4), p. 172-174, 2001. [cited by applicant]
Extended European Search Report, European Patent Application No. 17776577.3, dated Nov. 7, 2019, 8 pages. [cited by applicant]
Extended European Search Report, European Patent Application No. 18864067.6, Nov. 11, 2020, eight pages. [cited by applicant]
Extended European Search Report, European Patent Application No. 20782636.2, 9, Dec. 9, 2022, 14 pages. [cited by applicant]
Findlay, M. et al., “Measurement of Plasma 5-Fluorouracil by High-Performance Liquid Chromatography with Comparison of Results to Tissue Drug Levels Observed Using in Vivo 19F Magnetic Resonance Spectroscopy in Patients… [cited by applicant]
Fischel, J-L. et al., “Experimental Arguments for a Better Understanding of Hand-Foot Syndrome Under Capecitabine”, Proceedings of the American Association for Cancer Research, 2004, p. 487 (Abstract #2119), vol. 45. [cited by applicant]
Fujii, S. et al., “Effect of Coadministration of Uracil or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents,” Gann., vol. 70, pp. 209-2… [cited by applicant]
Fukushima, S. et al., “Carcinogenicity of Uracil, a Nongenotoxic Chemical, in Rats and Mice and Its Rationale”, Cancer Research, 1992, pp. 1675-1680, vol. 52. [cited by applicant]
Gallen, C.C. et al., “Magnetoencephalography and Magnetic Source Imaging: Capabilities and Limitations”, Functional Neuroimaging, 1995, pp. 227-249, vol. 5. [cited by applicant]
Gallo, R. et al., “The Enzymatic Mechanisms for Deoxihymidine Synthesis in Human Leukocites,” The Journal of Clinical Investigation, vol. 48, pp. 82-93, 1969. [cited by applicant]
Georgopoulos, A. et al., “Synchronous Neural Interactions Assessed by Magnetoencephalography: A Functional Biomarker for Brain Disorders”, Journal of Neural Engineering, 200, pp. 349-355, vol. 4. [cited by applicant]
Giani, A.S., et al., “Detecting Tones in Complex Auditory Scenes,” NeuroImage, Nov. 2015, vol. 122, pp. 203-213. [cited by applicant]
Gmehlin, D. et al., “Age Effects on Preattentive and Early Attentive Auditory Processing of Redundant Stimuli: Is Sensory Gating Affected by Physiological Aging?” Journal of Gerontology A Biol. Sci. Med Sci., 2011, pp. … [cited by applicant]
Golubic, SJ et al., “MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating,” Hum. Brain Mapp., 2017, vol. 38, pp. 5180-5194. [cited by applicant]
Gramfort, A., et al. “Graph-Based Variability Estimation in Single-Trial Event-Related Neural Responses,” IEEE Trans. on Biomedical Engineering, May 2010, vol. 57, No. 5, pp. 1051-1061. [cited by applicant]
Gramfort, A., et al., “MEG and EEG data analysis with MNE-Python,” Frontiers in Neuroscience, 2013, vol. 7, Article 267, pp. 1-13. [cited by applicant]
Hamalainen, M. et al., “Magnetoencephalography—Theory, Instrumentation, and Applications to Noninvasive Studies of the Working Human Brain”, Reviews of Modern Physics, Apr. 1993, pp. 413-497, vol. 65, No. 2. [cited by applicant]
Hari, R., “The Neuromagnetic Method in the Study of the Human Auditory Cortex,” Auditory Evoked Magnetic Fields and Electric Potentials, by Grandori et al. ed., Karger: Basel, Switzerland, 1990, pp. 222-282. [cited by applicant]
Hartmann, H.R. et al., “Modulation of the Effects of Fluoropyrimidines on Toxicity and Tumor Inhibition in Rodents by Uridine and Thymidine,” Med. Oncol. & Tumor Pharmacother., vol. 3(2), pp. 111-118, 1986. [cited by applicant]
Harvey, S.C., “Drug Absorption, Action and Disposition,” Chapter 35 in Remington's Pharmaceutical Sciences, 18th Ed., Gennaro et al. (eds.), 1990, Mack Publishing Co., Easton, PA, pp. 697-724. [cited by applicant]
Harvey, S.C., “Topical Drugs,” Chapter 38 in Remington's Pharmaceutical Sciences, 18.sup.th Ed., Gennaro et al. (eds.), 1990, Mack Publishing Co., Easton, PA, pp. 757-773. [cited by applicant]
Hatfield, D. et al., “Synthesis of (3-Ribosyluric Acid) 5-Phosphate and (3-Ribosylxanthine) 5-Phosphate by a Pyrimidine Ribonucleotide Pyrophosphorylase of Beef Erythocytes,” The Journal of Biological Chemistry, pp. 60-… [cited by applicant]
Hejna, M. et al., “Decrease of Duration and Symptoms in Chemotherapy-Induced Oral Mucositis by Topical GM-CSF: Results of a Prospective Randomised Trial,” European Journal of Cancer, vol. 37(16), pp. 1994-2002, 2001. [cited by applicant]
Hirata, K. et al., “Pharmacokinetic Study of S-1, A Novel Oral Fluorouracil Antitumor Drug,” Clinical Cancer Research, Aug. 1999, pp. 2000-2005, vol. 5. [cited by applicant]
Hoff, P., “The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL.TM.) and S-1: A Review of Their Clinical Development and Therapeutic Potential,” Investigational New Drugs… [cited by applicant]
Ichikawa, W. et al., “Both Gene Expression for Orotate Phosphoribosyltransferase and its Ratio to Dihydropyrimidine Pehydrogenase Influence Outcome Following Fluoropyrimidine-Based Chemotherapy for Metastatic Colorectal… [cited by applicant]
Ikenaka, K. et al., “Effect of Uracil on Metabolism of 5-Fluorouracil In Vitro,” Gann., vol. 70, pp. 353-359, 1979. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/IB2020/053219, Sep. 4, 2020, seventeen pages. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/US2013/047289, Feb. 11, 2014, 12 pages. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/US2017/024813, Aug. 14, 2017, seventeen pages. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/US2018/054228, Dec. 11, 2018, eighteen pages. [cited by applicant]
International Search Report and Written Opinion, Patent Cooperation Treaty Application No. PCT/US2022/045839, Jan. 27, 2023, 23 pages. [cited by applicant]
Jacobi, M., “Brainwaves and Consciousness—Brainwaves (1) Beta, Alpha, Theta and Delta,” 2002-2014, May be Retrieved at<URL:http://www.hirnwellen-und-bewusstsein.de/brainwaves_1.html, Jan. 18, 2008. [cited by applicant]
Johnson, M.R. et al., “Life Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-Deficient Patient After Treatment with Topical 5-Fluorouracil,” Clinical Cancer Research, Aug. 1999, pp. 2006-2011, vol. 5. [cited by applicant]
Kawaguchi, Y. et al., “Studies on the Metabolism of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Uracil Co-Administered Orally to Tumor-Bearing Rats,” Gann., vol. 19, pp. 869-899, 1980. [cited by applicant]
Kligfield et al., “Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part I: The Electrocardiogram and Its Technology: A Scientific Statement From the American Heart Association Electr… [cited by applicant]
Knuutila, J. et al., “Large-Area Low-Noise Seven-Channel dc SQUID Magnetometer for Brain Research,” Rev. Sci. Instrum., Nov. 1987, pp. 2145-2156, vol. 58. [cited by applicant]
Kowanko et al., Prevention and Treatment of Oral Mucositis in Cancer Patients, Best Practice, 1998, pp. 1-6, vol. 2, Issue 3. Available at http:/Joralcancerfoundation_org/dental/pdf/mucositis.pdf, 6 pages. [cited by applicant]
Largillier, R. et al., “Prospective Analysis of Dihydropyrimidine Dehydrogenase (DPD) Activity for Predicting Capecitabine-Related Toxicities in Metastatic Breast Cancer Patients,” (Roser Abstract), p. 39, 2002. [cited by applicant]
Laukka, E.J. et al., “Effects of Between-Person Differences and Within-Person Changes in Symptoms of Anxiety and Depression on Older Age Cognitive Performance,” Psychological Medicine, 2017, pp. 1350-1358. [cited by applicant]
Leo, S. et al., “Dermatological Toxicity from Chemotherapy Containing 5-Fluorouracil,” Journal of Chemotherapy, vol. 6(6), pp. 2-5, 1994. [cited by applicant]
Levy, S. et al., “A Pharmacokinetic Evaluation of 0.5% and a 5% Fluorouracil Topical Cream in Patients with Actinic Keratosis,” Clinical Therapeutics, vol. 23(6), pp. 908-920, 2001. [cited by applicant]
Luccioni et al., “Pyrimidine Nucleotide Metabolism in Human Colon Carcinomas: Comparison of Normal Tissues Primary Tumors and Xenografts,” Int. J. Cancer, vol. 58, pp. 32-. [cited by applicant]
MacKean, M. et al., “Phase I and Pharmacologic Study of Intermittent Twice-Daily Oral Therapy with Capecitabine in Patients with Advanced and/or Metastatic Cancer,” Journal of Clinical Oncology, vol. 16(9), pp. 2977-298… [cited by applicant]
Maehara, Y. et al., “Scientific Basis for the Combination of the Tegafur with Uracil,” Oncology, vol. 11(9), Supplement No. 10, pp. 14-21, 1997. [cited by applicant]
Makris, N. et al., “Human Cerebral Cortex: A System for the Integration of Volume- and Surface-Based Representations,” NeuroImage, pp. 139-153, 2006, vol. 33. [cited by applicant]
Malet-Martino, M. et al., “Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT,S-1): A Review,” The Oncologist, 2002, pp. 288-323, vol. 7. [cited by applicant]
Miller, G., “Feedback from Frontal Cortex May Be a Signature of Consciousness,” Science, May 13, 2011, p. 779, vol. 332. [cited by applicant]
Mountz, J.M. et al., “Comparison of Qualitative and Quantitative Imaging Characteristics of [ [cited by applicant]
Naguib, F.N.M. et al., “Enzymes of Uracil Catabolismin Normal and Neoplastic Human Tissues,” Cancer Research, Nov. 1985, pp. 5405-5412, vol. 45. [cited by applicant]
Nairn, J. G., “Solutions, Emulsions, Suspensions and Extracts,” Chapter 83 in Remington's Pharmaceutical Sciences, 18 [cited by applicant]
Nesselroade, J.R. et al., “Methodological and Theoretical Implications of Intraindividual Variability in Perceptual-Motor Performance,” Journal of Gerontology, 2004, vol. 59B, No. 2, pp. P49-P55. [cited by applicant]
Nichols, T., et al., “Nonparametric permutation tests for functional neuroimaging: A primer with examples”, Human Brain Mapping, vol. 15, Issue1, Jan. 2002, pp. 1-25, XP055291962, ISSN: 1065-9471, DOI: 10.1002/hbm.1058. [cited by applicant]
Niedzwicki, J. et al., “Structure-Activity Relationship of Pyrimidine Base Analogs of Ligands of Orotate Phosphoribosyltransferase,” Biochemical Pharmacology, vol. 33(15), pp. 2383-2395, 1984. [cited by applicant]
Park, D. et al., “Activation of CaMKIV by Soluble Amyloid-β1-42 Impedes Trafficking of Axonal Vesicles and Impairs Activity-Dependent Synaptogenesis,” Science Signaling, Jul. 11, 2017, vol. 10, No. 487, 12 pages. [cited by applicant]
Partial Supplementary European Search Report for EP13810531.7, dated Feb. 10, 2016, 7 pages. [cited by applicant]
Pekkonen, E. et al., “Impaired Preconscious Auditory Processing and Cognitive Functions in Alzheimer's Disease,” Clinical Neurophysiology, 1999, vol. 110, pp. 1942-1947. [cited by applicant]
Powis, G., “Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents,” International Encyclopedia of Pharmacology and Therapeutics, pp. 42-50, 1994. [cited by applicant]
Pugh et al. (eds.), Stedman's Medical Dictionary, 27th Edition, Lippincott Williams & Wilkins, Baltimore, MD, 2000, see pp. 365, 613-617 & 620 (“carcinoma,” “dermatitis,” “dermatosis & dermatoses”). [cited by applicant]
Roberts, T.P.L. et al., “MEG Detection of Delayed Auditory Evoked Responses in Autism Spectrum Disorders: Towards an Imaging Biomarker for Autism”, Autism Research, Feb. 2010, pp. 8-18, vol. 3, No. 1. [cited by applicant]
Sabbagh, M.N. et al., “Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data,” Neurol. Ther., 2017, vol. 6, (suppl 1), pp. S83-S95. [cited by applicant]
Samid, D., “Important Information About Xeloda (Capecitabine) Tablets,” Roche Laboratories Inc., 2003, pp. 29-31. [cited by applicant]
Sawada, N. et al., “Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts,” Clinical Cancer Research, Apr. 1998, pp. 1013-1019, vol. 4. [cited by applicant]
Schilsky, R.L. et al., “Sixty-Third Meeting of the Oncologic Drug Advisory Committee,” Food and Drug Administration Center for Drug Evaluation and Research, 1999. [cited by applicant]
Senff, H. et al., “Topical 5-Fluorouracil Solution in the Treatment of Warts—Clinical Experience and Percutaneous Absorption,” British Journal of Dermatology, vol. 118, pp. 409-414, 1968. [cited by applicant]
Sigma U.S. Catalog, “Biochemical and Reagents for Life Science Research,” St. Louis, MO, 2000-2001 edition, only p. 1000 supplied. [cited by applicant]
Sludden, J. et al., “Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse,” Pharmacology, pp. 276-280, 1998. [cited by applicant]
Spicer, E. et al., “Toxicity Study of Uracil in Dogs,” Journal of Applied Toxicity, vol. 5, pp. 199-204, 1985. [cited by applicant]
Stein, J.H. et al., Editor-in-Chief, Internal Medicine, 4th Edition, Chapters 71 and 72, pp. 699-715, 1994. [cited by applicant]
Stokes, M. G., et al. “Simple Metric for Scaling Motor Threshold Based on Scalp-Cortex Distance: Application to Studies Using Transcranial Magnetic Stimulation,” Journal of Neurophysiology, 2005, pp. 4520-4527, vol. 94,… [cited by applicant]
Sweatt, J.D., “Creating Stable Memories,” Science, Feb. 18, 2011, pp. 869-870, vol. 331. [cited by applicant]
Swinyard, E.A. et al., “Pharmaceutical Necessities,” Chapter 66 in Remington's Pharmaceutical Sciences, 18th Ed., Gennaro et al. (eds.), 1990, Mack Publishing Co., Easton, PA, pp. 1286-1329. [cited by applicant]
Taulu, S. et al., “Removal of Magnetoencephalographic Artifacts with Temporal SignalSpace Separation: Demonstration with Single-Trial Auditory-Evoked Responses,” Human Brain Mapping, 2009, pp. 1524-1534, vol. 30. [cited by applicant]
Taulu, S. et al., “Spatiotemporal Signal Space Separation Method for Rejecting Nearby Interference in MEG Measurements,” Physics in Medicine and Biology, 2006, 11 pages, vol. 51, No. 7. [cited by applicant]
Taulu, S. et al., “Suppression of Interference and Artifacts by the Signal Space Separation Method,” Brain Topography, Summer 2004, pp. 269-275, vol. 16, No. 4. [cited by applicant]
U.S. Appl. No. 60/355,764, filed Feb. 12, 2002, Inventor John P. Ford. [cited by applicant]
U.S. Appl. No. 60/697,910, filed Jul. 8, 2005, Inventor John P. Ford. [cited by applicant]
U.S. Appl. No. 60/933,038, filed Jun. 4, 2007, Inventor John P. Ford. [cited by applicant]
U.S. Appl. No. 61/069,031, filed Mar. 12, 2008, Inventor John P. Ford. [cited by applicant]
U.S. Appl. No. 61/666,171, filed Jun. 29, 2012, Inventor John P. Ford. [cited by applicant]
U.S. Appl. No. 62/315,376, filed Mar. 30, 2016, Inventor John P. Ford. [cited by applicant]
United States Office Action, U.S. Appl. No. 17/745,115, filed Nov. 18, 2022, 7 pages. [cited by applicant]
Vanden Heuvel, J.P. et al., “Differential Nucleobase Protection Against 5-Fluorouracil Toxicity for Squamous and Columnar Cells: Implication for Tissue Function and Oncogenesis,” Investigational New Drugs, Jul. 1, 2015,… [cited by applicant]
Venes et al.(eds.), Taber's Cyclopedic Medical Dictionary, 21st Edition, F. A. Davis Co., Philadelphia, PA, 2009, see pp. 285-289 (“carcinoma”). [cited by applicant]
Wang, J. et al., “Oral 5-FU is a More Effective Antimetastatic Agent than UFT,” Anticancer Research, 2004, pp. 1353-1360, vol. 24. [cited by applicant]
Weast et al., CRC Handbook of Chemistry and Physics, Boca Raton, FL, 1981, only p. C-536 supplied: see entry for “Uracil.”. [cited by applicant]
Williamson, S.J. et al., “Biomagnetism,” Journal of Magnetism and Magnetic Materials, 1981, pp. 129-201, vol. 22, No. 2. [cited by applicant]
Xeloda (Capecitabine) Tablets Product Label Insert, Roche Pharmaceuticals, 2003, 47 pages. [cited by applicant]
Zamrini, E. et al., “Magnetoencephalography as a Putative Biomarker for Alzheimer's Disease,” International Journal of Alzheimer's Disease, 2011, pp. 1-10, vol. 2011. [cited by applicant]
Zografi et al., “Disperse Systems,” Chapter 19 in Remington's Pharmaceutical Sciences, 18.sup.th Ed., Gennaro et al. (eds.), 1990, Mack Publishing Co., Easton, PA, only pp. 257-309 supplied. See in particular p. 302 (“E… [cited by applicant]
Baillet, S., “Magnetoencephalography for brain electrophysiology and imaging,” Nature Neuroscience, vol. 20, No. 3, Mar. 2017, pp. 327-339. [cited by applicant]
Brookes, M.J. et al. “Magnetoencephalography with optically pumped magnetometers (OPM-MEG): the next generation of functional neuroimaging,” Trends in Neurosciences, vol. 45, No. 8, Aug. 2022, pp. 621-634. [cited by applicant]
Grubbs, F.E., “Sample Criteria for Testing Outlying Observations,” The Annals of Mathematical Statistics, vol. 21, No. 1, Mar. 1950, pp. 27-58. [cited by applicant]
Hanna-Pladdy, B. et al., “Functional Magnetic Resonance Imaging Biomarkers Predicting Cognitive Progression in Parkinson Disease: Protocol for a Prospective Longitudinal Cohort Study,” JMIR Research Protocols, vol. 8, I… [cited by applicant]
Hurd, M.D et al., “Monetary Costs of Dementia in the United States,” The New England Journal of Medicine, 368(14), Apr. 2013, pp. 1326-1334. [cited by applicant]
Joshi, A. et al., “Reducing between scanner differences in multi-center PET studies,” NeuroImage, vol. 46, Feb. 6, 2009, pp. 154-159. [cited by applicant]
Krashes, M.J. et al., “Rapid, reversible activation of AgRP neurons drives feeding behavior in mice,” The Journal of Clinical Investigation, vol. 121, No. 4, Apr. 2011, pp. 1424-1428. [cited by applicant]
Lezak, M., “Neuropsychological Assessment,” Fifth Edition, Oxford, UK: Oxford University Press, Mar. 22, 2012 (table of contents only). [cited by applicant]
Logothetis, N.K. “What we can do and what we cannot do with fMRI,” Nature, vol. 453(7197), Jun. 12, 2008, pp. 869-878. [cited by applicant]
López-Sanz, D. et al., “Magnetoencephalography applied to the study of Alzheimer's disease,” Progress in Molecular Biology and Translational Science, vol. 165, 2019, pp. 25-61. [cited by applicant]
Mason, J.W. et al., “Recommendations for the Standardization and Interpretation of the Electrocardiogram,” Circulation, vol. 115, Iss. 10, Feb. 23, 2007, pp. 1325-1332. [cited by applicant]
Medina, R. et al., “Electrophysiological Brain Changes Associated with Cognitive Improvement in a Pediatric Attention Deficit Hyperactivity Disorder Digital Artificial Intelligence-Driven Intervention: Randomized Contro… [cited by applicant]
Nunez, P. et al., “Electric Fields of the Brain: The Neurophysics of EEG,” Second Edition, Oxford, UK: Oxford University Press, 2006 (table of contents only). [cited by applicant]
Poldrack, R.A., “Inferring Mental States from Neuroimaging Data: From Reverse Inference to Large-Scale Decoding,” Neuron, vol. 72, No. 5 Dec. 8, 2011, pp. 692-697. [cited by applicant]
Ramirez, S. et al., “Creating a False Memory in the Hippocampus,” Science, vol. 341(6144), Jul. 26, 2013, pp. 387-391. [cited by applicant]
Sherkow, U.S., “CRISPR: Pursuit of profit poisons collaboration,” Nature, vol. 532(7598), Apr. 14, 2016, pp. 172-173. [cited by applicant]
Vogel, J.W. et al., “Four distinct trajectories of tau deposition identified in Alzheimer's disease,” Nature Medicine, vol. 27(5), Apr. 29, 2021, pp. 871-881. [cited by applicant]
Wang, Y. et al., “Viral vectors as a novel tool for clinical and neuropsychiatric research applications,” General Psychiatry 31(2), Oct. 2018, pp. 1-9. [cited by applicant]